Home
About
Publications Trends
Recent Publications
Expert Search
Archive
high risk patients
How Can High-Risk Patients Be Identified?
High-risk patients can be identified through a combination of methods:
Genetic Testing
: Identifies mutations that increase cancer risk.
Family History Assessment
: Evaluates the prevalence of cancer in close relatives.
Lifestyle and Environmental Assessment
: Reviews lifestyle choices and exposure to known carcinogens.
Medical History
: Considers pre-existing conditions that may elevate risk.
Frequently asked queries:
Who Are High-Risk Patients?
How Can High-Risk Patients Be Identified?
What Are the Challenges in Managing High-Risk Patients?
Can Tumor Shrinkage be Temporary?
What is a False Diagnosis?
Can Germ Cell Tumors be Prevented?
Why Are These Tests Important?
What Impact Do Cancer Charities Have on Society?
Can Invasion be Targeted for Cancer Treatment?
What is Neurofibromatosis Type 2?
What Role Do Family and Friends Play in Reducing Cancer-Related Anxiety?
What Role Do Clinical Trials Play in Regulatory Decisions?
Can biodegradable materials improve imaging and diagnosis of cancer?
What Are Non-Functional Tumors?
Are There Any Special Considerations for Palliative Care?
How Do Epigenetic Drugs Work?
What advances in cancer research contribute to stronger therapeutic approaches?
Can Internal Leaks Be Prevented?
What Role Does Personal Hygiene Play in Infection Prevention?
How Can Cancer Patients Balance Work and Treatment?
Top Searches
Brain Tumor
Breast cancer
cancer
Cancer Diagnostics
Cancer Genomics
Chemotherapy
hepatocellular carcinoma
Lung Cancer
Nanotechnology
Non-Hodgkin’s Lymphoma
Radiation-Induced Malignancies
Follow Us
Facebook
Linkedin
Youtube
Instagram
Partnered Content Networks
Relevant Topics
4D Segmentation
Alopecia
Atlas-based Segmentation
Automated Segmentation
B-cell malignancies
biomarkers
Brain Tumor
Brain Tumor Segmentation
Breast cancer
cancer
cancer diagnosis
Cancer Genome Atlas
Cancer genomics
Cancer treatment
CAR T-cell therapy
Carcinogenesis
cell adhesion
cell migration
cell-free RNA
chemotherapy
Chromatin remodeling genes
Chronic inflammation
CIAbimatoprost
circulating tumor cells
circulating tumor DNA
Co-morbidity
Combination therapy
Copy number variations
cytokine release syndrome
Deep Learning
Diagnosis challenges
diffuse large B-cell lymphoma
DNA damage
docetaxel-cyclophosphamide
Drug delivery
early detection
epirubicin-cyclophosphamide
exosomes
extracellular matrix
Fibrosis
Genetic alteration
Glioblastoma
Gold nanoparticles
Hepatocellular carcinoma
High Tumor
image-guided radiotherapy
Imaging Techniques
Immunosuppression
Immunotherapy
Integrative genomics
integrin inhibitors
Integrins
intensity-modulated radiation therapy
Keratinocyte
Lipid-based nanoparticles
Liquid biopsy
liver cancer
long-term cancer risks
Lung cancer
Machine Learning
Magnetic Resonance Imaging
metastasis
methyltransferase
minimal residual disease
MRI
Multi-modal Imaging
Multidisciplinary care
Mutual exclusivity analysis
Nanoparticles
Nanotechnology
neoadjuvant radiotherapy
neurotoxicity
Next-generation sequencing
nnovative Biomarkers
Non-Hodgkin’s lymphoma
non-invasive diagnostics
Novel Biomarkers for Brain Tumors
Novel Chemotherapy
Oncogenic transcription factors
oncological diseases
paclitaxel
Personalized medicine
Photobiomodulation therapy
Polymeric nanoparticles
portal vein tumor thrombus
precision medicine
Probabilistic Models
proton therapy
Radiation-induced malignancies
radiotherapy
refractory lymphoma
relapsed lymphoma
Risk factors
secondary cancer prevention
secondary cancers
Silver nanoparticles
stereotactic body radiation therapy
Targeted therapy
Tolerability
transarterial chemoembolization
Tuberculosis
tumor microenvironment
tumor progression
Voltage-gated sodium channels
Subscribe to our Newsletter
Stay updated with our latest news and offers related to Cancer.
Subscribe